DE69533311D1 - Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen - Google Patents

Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Info

Publication number
DE69533311D1
DE69533311D1 DE69533311T DE69533311T DE69533311D1 DE 69533311 D1 DE69533311 D1 DE 69533311D1 DE 69533311 T DE69533311 T DE 69533311T DE 69533311 T DE69533311 T DE 69533311T DE 69533311 D1 DE69533311 D1 DE 69533311D1
Authority
DE
Germany
Prior art keywords
interferon
type
autoimmune diseases
treating autoimmune
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69533311T
Other languages
English (en)
Other versions
DE69533311T2 (de
Inventor
Staley Armstrong Brod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26920717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69533311(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of DE69533311D1 publication Critical patent/DE69533311D1/de
Application granted granted Critical
Publication of DE69533311T2 publication Critical patent/DE69533311T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69533311T 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen Expired - Fee Related DE69533311T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22663194A 1994-04-12 1994-04-12
US226631 1994-04-12
US40827195A 1995-03-24 1995-03-24
US408271 1995-03-24
PCT/US1995/004420 WO1995027502A1 (en) 1994-04-12 1995-04-11 Method of treating auto-immune diseases using type one interferons

Publications (2)

Publication Number Publication Date
DE69533311D1 true DE69533311D1 (de) 2004-09-02
DE69533311T2 DE69533311T2 (de) 2005-07-21

Family

ID=26920717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533311T Expired - Fee Related DE69533311T2 (de) 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Country Status (13)

Country Link
EP (1) EP0752884B1 (de)
JP (1) JPH09511989A (de)
KR (1) KR100424212B1 (de)
AT (1) ATE271879T1 (de)
AU (1) AU695260B2 (de)
CA (1) CA2187550A1 (de)
DE (1) DE69533311T2 (de)
DK (1) DK0752884T3 (de)
ES (1) ES2224124T3 (de)
IL (1) IL113280A (de)
NZ (1) NZ284276A (de)
SA (1) SA95160081B1 (de)
WO (1) WO1995027502A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
JP3806445B2 (ja) * 1996-05-09 2006-08-09 ファーマ・パシフィック・プロプライエタリー・リミテッド 治療方法
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
JP2003527090A (ja) * 1999-08-27 2003-09-16 マキシゲン・エイピーエス 新規なインターフェロンベータ様分子
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
WO2004058295A1 (ja) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. 類天疱瘡治療剤
AU2019276776A1 (en) * 2018-06-01 2020-11-19 ILC Therapeutics Limited Compositions and methods relating to the treatment of diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease

Also Published As

Publication number Publication date
EP0752884A1 (de) 1997-01-15
JPH09511989A (ja) 1997-12-02
ES2224124T3 (es) 2005-03-01
ATE271879T1 (de) 2004-08-15
IL113280A0 (en) 1995-07-31
AU695260B2 (en) 1998-08-13
DE69533311T2 (de) 2005-07-21
CA2187550A1 (en) 1995-10-19
EP0752884A4 (de) 1999-04-07
IL113280A (en) 2004-12-15
NZ284276A (en) 2000-07-28
AU2283995A (en) 1995-10-30
WO1995027502A1 (en) 1995-10-19
EP0752884B1 (de) 2004-07-28
KR970702063A (ko) 1997-05-13
SA95160081B1 (ar) 2005-09-19
KR100424212B1 (ko) 2004-07-21
DK0752884T3 (da) 2004-11-22

Similar Documents

Publication Publication Date Title
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DK0880350T3 (da) Behandling af dissemineret sklerose
BR9709068A (pt) Processo de tratamento.
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE58902737D1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE232093T1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
DE69614375D1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE297722T1 (de) Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
DE69622472D1 (de) Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
AT383612B (de) Verfahren zur herstellung eines neuen antigenen proteins des maul- und klauenseuchevirus
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
DE3855159D1 (de) Thienotricyclen zur Behandlung von Erkrankungen der Bronchien
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee